Introduction {#s1}
============

Genome-wide interrogation approaches for mapping genes often are designed to detect the common variants associated with common phenotypes or disease, generally leaving rare variants undetected or untested [@pgen.1001318-Ma1]--[@pgen.1001318-Smith1]. The Rare Allele--Major Effects (RAME) model postulates that rare (minor allele frequency \<0.01 to 0.05) penetrant variants are key to the genetic etiology of common disease. Functional mutations that lead to an altered amino acid are often deleterious and potentially disease causing. Such mutations are subjected to natural selection, which either removes these alleles from the population or maintains them at low frequencies relative to the neutral expectations [@pgen.1001318-Pritchard1], [@pgen.1001318-Pritchard2], [@pgen.1001318-Crow1]--[@pgen.1001318-Kryukov1]. Partial genome or candidate gene resequencing of a large number of individuals holds the promise of finding both common and rare variants associated with clinically relevant phenotypes [@pgen.1001318-Pritchard1], [@pgen.1001318-Pritchard2]. While a number of studies have mapped common mutations or structural variants associated with neurological disorders like Autism Spectrum Disorder (ASD) (e.g. [@pgen.1001318-Wang1]) and Schizophrenia (e.g. [@pgen.1001318-Stefansson1]), the RAME model is better suited for modelling diseases that occur sporadically in families, and for testing whether rare variants contribute to these disorders.

ASD is a neurodevelopmental disorder characterized by stereotyped and repetitive behaviours and impairments in social interactions. Schizophrenia is a chronic psychiatric syndrome characterized by a profound disruption in cognition, behaviour and emotion, which begins in adolescence or early adulthood. The incidence of both ASD and schizophrenia is higher in males than in females [@pgen.1001318-Lewis1], [@pgen.1001318-Skuse1], which points to an important role of X-chromosome genes in the two diseases. There is significant clinical variability among ASD and schizophrenia patients, suggesting that they are etiologically and genetically heterogeneous. For ASD, genetics clearly plays an important role in the etiology, as revealed by twin and familial studies [@pgen.1001318-Bailey1]--[@pgen.1001318-Bolton1]. Some susceptibility regions have been identified through whole genome linkage analyses [@pgen.1001318-Gupta1], [@pgen.1001318-Klauck1], although they rarely coincide among the different studies [@pgen.1001318-Yang1]. Additionally, *de novo* mutations have been observed [@pgen.1001318-Sebat1], [@pgen.1001318-Awadalla1] and are candidate variants in sporadic cases of either ASD or schizophrenia, but they explain a small percentage of the phenotypic variation. Together, these observations suggest that disruption of numerous genes by rare yet penetrant mutations could represent a major cause of ASD. Schizophrenia has an estimated heritability of 80% [@pgen.1001318-Tandon1], and it has been recently associated with common variants at the MHC locus [@pgen.1001318-Stefansson1], [@pgen.1001318-Purcell1], [@pgen.1001318-Shi1]. There are also several observations suggesting a causal link between rare mutations and schizophrenia, such as the fact that patients mostly have no affected close relatives, or the associations of both paternal age and decreased fertility with the disease [@pgen.1001318-McClellan1]. Recent studies also reported *de novo* copy number variants (CNVs) in schizophrenia, providing further support for the rare variant hypothesis in non-familial cases [@pgen.1001318-Walsh1]--[@pgen.1001318-TheInternationalSchizophreniaConsortium1], as well as an excess of rare inherited CNVs in familial cases [@pgen.1001318-Xu2].

We hypothesized that capturing genetic variation at low frequencies (minor allele frequency ≥0.005) in a large set of genes expressed in the brain will significantly contribute to our understanding of the genetic basis of ASD and schizophrenia. If the RAME model is relevant to these two diseases, the expectation is an enrichment of rare deleterious mutations among individuals diagnosed with ASD and schizophrenia. Here, we use population genetic and other statistical methods to analyze a resequencing dataset to map genes associated to these two disorders. Using this approach, we identified candidate genes by testing for genes harboring an excess of rare missense variants among individuals affected with ASD and schizophrenia, testing for selection at the gene level in each disease cohort, and assessing the impact of the variants found in candidate genes on the study-wide distribution of missense allele frequencies for each disease cohort.

Results {#s2}
=======

SNPs Discovered from Deep Resequencing {#s2a}
--------------------------------------

We resequenced 408 selected brain-expressed genes ([Table S1](#pgen.1001318.s005){ref-type="supplementary-material"}) in 142 ASD and 143 schizophrenia-affected individuals [@pgen.1001318-Awadalla1]. The ASD and schizophrenia cohorts had global ethnicity representation yet were predominantly European with a large French Canadian sub-group. It is crucial to exclude ethnic and genetic outliers when analyzing rare variants because such samples contain private alleles from other populations. While the results from the software *structure* [@pgen.1001318-Pritchard3] revealed no population structure, we identified and removed potential ethnic outliers from the analysis using self reported ethnicity and a principle component analysis using eignesoft [@pgen.1001318-Price1] (see [Materials and Methods](#s4){ref-type="sec"}, [Figure S1](#pgen.1001318.s001){ref-type="supplementary-material"}). The result was a sample of individuals of European ancestry: ASD (*n* = 102) and schizophrenia (*n* = 138). A total of 285 samples from the Québec Newborn Twin Study (QNTS) [@pgen.1001318-Lemelin1] were screened for self reported European ancestry (*n* = 240) and were used as controls. Thirty-eight (19 autosomal, 19 X-linked) of the 408 brain expressed genes were sequenced in the QNTS controls, including any gene with *de novo* mutations previously described in one of the disease cohorts [@pgen.1001318-Awadalla1] or with potential protein disrupting mutations.

We identified a total of 5,396 segregating sites in the disease cohorts, including 1,111 missense and 11 nonsense variants ([Table 1](#pgen-1001318-t001){ref-type="table"} and [Table 2](#pgen-1001318-t002){ref-type="table"}), from lymphoblastoid cell DNA. As expected, there was a reduction in nucleotide diversity (*π*) on the X chromosome relative to autosomes by a ratio of 0.76 ([Table 1](#pgen-1001318-t001){ref-type="table"}), consistent with neutral expectations for the reduced effective population size of the X chromosome [@pgen.1001318-Hartl1]. The ratio of the male to female population mutation rate [@pgen.1001318-Miyata1] was estimated to be 6.37, slightly higher but similar to previous estimates of the male mutation rate being four times the female mutation rate [@pgen.1001318-Nachman1]. The population mutation rate (θ~W~ per base pair) for all variants (including nonsense mutations) was 3.471×10^−4^ and 3.47×10^−4^ for Schizophrenia and ASD, respectively ([Table 1](#pgen-1001318-t001){ref-type="table"}).

10.1371/journal.pgen.1001318.t001

###### Segregating Sites and Diversity in the Disease Cohorts.

![](pgen.1001318.t001){#pgen-1001318-t001-1}

  Cohort                        Chromosome   Missense   Nonsense   Silent   Intronic   UTR   Splice   Total   *π*[\*](#nt102){ref-type="table-fn"} (per bp)   *θ~W~*[\*](#nt102){ref-type="table-fn"}(per bp)
  ---------------------------- ------------ ---------- ---------- -------- ---------- ----- -------- ------- ----------------------------------------------- -------------------------------------------------
  **ASD (N = 102)**              Autosome      574         3        772      1,870     69      1      3,289                    4.84×10^−4^                                      3.58×10^−4^
                                 X Chrom       124         1        153       508      40      0       826                     3.35×10^−4^                                      3.19×10^−4^
                                  Total        698         4        925      2,378     109     1      4,115                    4.39×10^−4^                                      3.47×10^−4^
  **SCZ (N = 138)**              Autosome      614         6        818      1,722     70      0      3,230                    4.45×10^−4^                                      3.54×10^−4^
                                 X Chrom       164         2        171       536      41      0       914                     3.58×10^−4^                                      3.10×10^−4^
                                  Total        778         8        989      2,258     111     0      4,144                    4.19×10^−4^                                      3.41×10^−4^
  **S2D (N = 240)**              Autosome      891         9       1,066     2,169     85      1      4,221                    5.23×10^−4^                                      3.48×10^−4^
                                 X Chrom       220         2        228       675      50      0      1,175                    3.96×10^−4^                                      3.18×10^−4^
                                  Total       1,111        11      1,294     2,844     135     1      5,396                    4.84×10^−4^                                      3.39×10^−4^
  **QNTS Control (N = 240)**     Autosome      108         0        103       217       5      1       434                     4.72×10^−4^                                      6.41×10^−4^
                                 X Chrom        18         1         7         14       5      0       45                      7.18×10^−5^                                      1.08×10^−4^
                                  Total        126         1        110       231      10      1       479                     2.72×10^−4^                                      3.75×10^−4^

π is mean pair-wise nucleotide diversity across all samples; θ~W~ is Watterson\'s mutation rate estimator based on the number of segregating sites.

\*Estimates were determined for each gene and then averaged across all genes.

10.1371/journal.pgen.1001318.t002

###### Nonsense Mutations in Disease Cohorts.

![](pgen.1001318.t002){#pgen-1001318-t002-2}

  Chr    Position[a](#nt104){ref-type="table-fn"}    Gene     Counts ASD               Counts SCZ               Counts QNTS Controls
  ----- ------------------------------------------ --------- ------------ ------------------------------------ ----------------------
  1                     20,886,681                   KIF17        0        1[\*](#nt105){ref-type="table-fn"}            0
  6                     43,846,749                   VEGFA        0                        2                             0
  6                     43,856,457                   VEGFA        1                        0                             0
  9                    103,472,993                  GRIN3A        0                        1                             0
  14                    71,241,195                  SIPA1L1       0                        1                             NA
  14                    72,813,605                   NUMB         0                        1                             NA
  17                    70,362,773                  GRIN2C        1                        0                             0
  19                     956,224                    GRIN3B        1                        0                             NA
  22                    49,506,476                  SHANK3        0        1[\*](#nt105){ref-type="table-fn"}            0
  X                     43,513,503                   MAOB         0                        1                             NA
  X                     69,395,157                   P2RY4        2                        2                             6

NA, not analyzed.

**^a^**Human Mar. 2006 (hg18) assembly.

\**de novo* mutations validated by resequencing parental tissue samples.

Rare Missense Variants Show Increased Predicted Detrimental Effects {#s2b}
-------------------------------------------------------------------

The fact that both ASD and Schizophrenia are highly heritability and that the common variant associations have been difficult to replicate support rare variants as an important component of the genetic etiology of these diseases. If rare variants are contributing to these diseases, we expect the site frequency spectrum (SFS) of missense variants to show an excess of deleterious, low frequency variants in our disease cohorts relative to either neutral expectations or controls. We analyzed the proposed detrimental effects of missense variants by estimating the potential functional effect of the missense variants observed using the software mapp [@pgen.1001318-Stone1]. Mapp was used to predict the severity of a missense mutation based on conservation in a multispecies protein alignment and the physiochemical properties of the amino acids. Severity scores indicated that 19% of the missense variants, in 47% of the genes with one or more missense variants, were likely to adversely affect protein function, considering a threshold for mapp scores of ten (approximately *P* = 0.01). Mapp scores are significantly higher for rare versus common variants (average 7.59 vs. 5.91, Mann-Whitney test *P* = 1.45×10^−4^, [Figure S2](#pgen.1001318.s002){ref-type="supplementary-material"}), and the proportion of variants with high mapp scores (\>10) is also significantly higher in the rare variants (21%) than in the common variants (11%) (χ^2^ = 8.3, *P* = 0.0039). These results are consistent with the presence of deleterious alleles being maintained at low frequency by selection. However, we did not observe an excess of high mapp scores in the cases relative to those in the QNTS controls indicating that rare mutations are likely subject to selection across all populations and not just cognitive related genes screened among our ASD and SCZ patients.

Individual Genes with Excess of Missense and Rare Missense Variants {#s2c}
-------------------------------------------------------------------

We applied three different methods to identify genes harboring an excess of rare missense variants in the disease cohorts. First, we identified genes with an excess of missense variants relative to the number of silent variants observed. For each gene, we used Fisher\'s Exact Test to test the ratio of missense to silent variants observed within the gene relative to the ratio of missense to silent variants found in the remaining pooled genes within each cohort, and separately for X-linked and autosomal loci. The ratio of missense to silent variants allows us to control for demographic effects on variation in each cohort and detect genes subject to natural selection. In both cohorts, the autosomal gene *MAP1A* exhibited a significant excess of missense compared to silent variants ([Figure S3](#pgen.1001318.s003){ref-type="supplementary-material"}, [Table S2](#pgen.1001318.s006){ref-type="supplementary-material"}) (ASD *P* = 0.04, schizophrenia *P* = 0.03 after Bonferroni correction) and 23 of the 29 missense variants described in this gene are rare (minor allele frequency \<0.03). *MAP1A* also exhibits an excess of missense variants when compared to the total counts of missense and silent variants in the control cohort (ASD-Control *P* = 0.009, Schizophrenia-Control *P* = 0.008). To further test the total predicted effect of the missense variants; for each gene, we summed the mapp scores for all missense variants within a gene, calculated the ratio of summed mapp scores to the number of silent variants, and compared these relative the same ratio in all other genes combined, separately for autosomal and X-linked loci. While the ratio for *MAP1A* was not significant after multiple testing correction, *GRIN3A* remained significant, relative to all other genes (*P* = 0.011) for the ASD cohort.

Second, we tested for an excess of individuals bearing rare missense variants, using Li and Leal\'s collapsing method [@pgen.1001318-Li1]. We 1) contrasted the ASD and schizophrenia cohorts to each other (*n* = 277 genes with one or more missense variant in at least one cohort), 2) compared ASD to the QNTS controls (*n* = 26 genes with one or more missense variant), and 3) compared the schizophrenia cohort to the QNTS controls (*n* = 26 genes with one or more missense variant), and corrected for multiple testing. For every gene, the number of individuals carrying at least one rare missense variant, and the number of individuals without rare missense variants, is compared between two cohorts (see [Materials and Methods](#s4){ref-type="sec"}). Although the ASD--Schizophrenia comparison revealed no significant results for any gene, we observed an excess of individuals with rare missense variants for two genes in the ASD cohort relative to the controls (*GRIN2B* and *CACNA1F*, Bonferroni adjusted *P* = 0.026, and *P* = 0.031 respectively, [Table S3](#pgen.1001318.s007){ref-type="supplementary-material"}). The schizophrenia cohort had a significant excess of individuals hosting rare missense variants at *GRIN2B* (*P* = 0.041). We repeated this analysis considering only missense variants predicted to have detrimental effects on protein function (mapp scores \>10). We found *GRIN3A* to exhibit an excess of individuals hosting rare detrimental missense variants in the ASD cohort relative to QNTS controls (*P* = 0.034).

Finally, we used an extension of the McDonald Krietman test, implemented in *mkprf* [@pgen.1001318-Bustamante1], to obtain estimates of *γ* per gene, based on our observed polymorphisms within humans and substitutions between humans and an outgroup (*Pan troglodytes*, see [Materials and Methods](#s4){ref-type="sec"}). Estimates of the population selection parameter *(γ^mkprf^* = 2*N~e~s*, where *N~e~* is the effective population size and *s* is the selection coefficient) will be negative when amino acid replacements are deleterious [@pgen.1001318-Bustamante2]. Here, we compared the per gene selection coefficients between cohorts to detect genes enriched for missense variants in one cohort compared to another. The overall distribution of *γ^mkprf^* values among genes was similar between ASD and schizophrenia ([Figure 1](#pgen-1001318-g001){ref-type="fig"}). When we contrasted ASD and schizophrenia *γ^mkprf^* estimates to those estimated from a Western-European population [@pgen.1001318-Bustamante2], we found both the ASD and schizophrenia cohorts have significantly more negative *γ^mkprf^* distributions (Wilcoxon paired test, ASD *P* = 0.0026, schizophrenia *P* = 0.0005), while the QNTS controls do not show significant differences relative to the Western-European dataset (*P* = 0.18). We also found individual genes that differed significantly among our cohorts. For example, we observed a significant difference in *γ^mkprf^* between the QNTS and ASD cohorts for *CACNA1F* ([Figure 1B](#pgen-1001318-g001){ref-type="fig"}), with the disease cohort having the lower *γ^mkprf^* estimate.

![Distribution of Individual Locus Selection Coefficients.\
Posterior mean and 95% CI of *γ^mkprf^* values by gene in the A) ASD and Schizophrenia (SCZ) cohorts, gene names colored purple are negatively selected in both cohorts (*γ^mkprf^* 95% CI\<0) and gene names in blue are positively selected in both cohorts (*γ^mkprf^* 95% CI\>0) B) ASD and Controls (QNTS, and Western European) and C) Schizophrenia and Controls (QNTS, and Western European).](pgen.1001318.g001){#pgen-1001318-g001}

The Overall Frequency Spectrum Reveals an Excess of Rare Deleterious Variants at Autosomal Loci among ASD and Schizophrenia Individuals {#s2d}
---------------------------------------------------------------------------------------------------------------------------------------

Having identified a number of individual genes with an excess of deleterious rare alleles, we examined the contribution of these individual genes to estimates of the population selection parameters, *γ^prfreq^*, across all variants within each cohort. Estimates of *γ^prfreq^* will be negative when an excess of low frequency variants are observed, suggesting an accumulation of deleterious variants [@pgen.1001318-Bustamante2] through negative selection. We used the Poisson Random Fields method implemented in *prfreq* [@pgen.1001318-Boyko1] to infer the demographic and selection parameters from cohort specific site frequency spectrum (SFS) and ask 1) whether the SFS of the missense variants showed evidence of selection relative to the SFS of silent and intronic variants; 2) if these selection estimates significantly differed between the disease cohorts and the control cohort; and 3) how removing the disease associated genes mapped with other approaches (see above) contribute to the SFS *γ^prfreq^* estimates.

First, we estimated the demographic parameters for the different cohorts using the silent and intronic variants discovered among all autosomal genes. Only genes having at least one or more variant (265 for disease cohorts, 19 for controls) were included. Next, while fixing the estimated demographic parameters, the population selection parameters (*γ^prfreq^*) were then estimated from the missense variants SFS (198 genes with one or more missense variant in the disease cohorts, 15 such genes for the controls; [Table S4](#pgen.1001318.s008){ref-type="supplementary-material"} and [Figure S4](#pgen.1001318.s004){ref-type="supplementary-material"}). In each case, we estimated the likelihood for that model including the likelihood for a Wright-Fisher neutral model. The demographic-only model was a significant improvement relative to the neutral model (two times the difference in log likelihood, *P*\<0.001), and the demographic-with-selection model was a significant improvement relative to the demographic-only model (*P*\<0.001)([Table S4](#pgen.1001318.s008){ref-type="supplementary-material"}). The estimates of *γ^prfreq^* were more negative in the two disease cohorts (*γ^prfreq^~ASD~* = −920, and *γ^prfreq^~SCZ~* = −1,100, [Table S4](#pgen.1001318.s008){ref-type="supplementary-material"} and [Figure S4](#pgen.1001318.s004){ref-type="supplementary-material"}) than for the control samples (*γ^prfreq^~control~* = −740), Specifically, the *γ^prfreq^~SCZ~* estimate was significantly more negative than the *γ^prfreq^~control~* estimate (*P* = 0.01), although this pattern was not observed for ASD (*P* = 0.12) (see [Materials and Methods](#s4){ref-type="sec"}). These observations indicate an excess of low frequency missense variants in our disease cohorts.

To assess each gene\'s contribution to the overall SFS, we developed an empirical distribution of *γ^prfreq^* estimates by removing each gene from the SFS and re-estimating *γ^prfreq^*. For ASD, when excluding *MAP1A*, *GRIN3B* and *RPGRIP1*, either individually or combined, the *γ^prfreq^* values became more positive (implying less deleterious effects; *γ^prfreq^~ASD~* = −880, P\[γ≥−880\| empirical distribution\] = 0.015 and −800 respectively) than when estimated for all variants (*γ^prfreq^~ASD~* = −920) ([Figure 2](#pgen-1001318-g002){ref-type="fig"}). These values are also closer to the *γ^prfreq^* value estimated in controls (*γ^prfreq^~control~* = −740, see above) and are at the most positive end of the empirical distribution of *γ^prfreq^* values ([Figure 2A](#pgen-1001318-g002){ref-type="fig"}). In the schizophrenia cohort, we estimated *γ^prfreq^* values when removing *MAP1A* and *GRIN3B* were *γ^prfreq^~SCZ~* = −1,020 (P\[γ≥−1020 \| empirical distribution\] = 0.01) and *γ^prfreq^~SCZ~* = −980 (P\[γ≥−920 \| empirical distribution\] = 0.005), respectively ([Figure 2B](#pgen-1001318-g002){ref-type="fig"}). When variants in both the *MAP1A* and *GRIN3B* loci were excluded from the SFS, the estimated *γ^prfreq^~SCZ~* increased to −880, again a value similar to that observed in controls. These results indicate that the presence of a few genes, enriched with rare missense variants in the disease cohorts, is enough to alter the global SFS among all of our candidate genes. In our case, the overall excess of deleterious missense variants and the more negative *γ^prfreq^* estimate in the two disease cohorts as compared to a neutral cohort is mainly caused by a very few candidate genes.

![Distribution of Population Selection Coefficients Estimated across All Loci.\
Variation in the population selection parameter (*γ^prfreq^* = 2*N~e~s*) obtained after excluding every gene with at least one missense variant (198) from the SFS for A) the ASD cohort; \* denotes *γ^prfreq^* estimated after removing *MAP1A*, *GRIN3B*, and *RPGRIP1*, and B) the Schizophrenia (SCZ) cohort; \* denotes *γ^prfreq^* estimated after removing *MAP1A* and *GRIN3B*. Genes producing the more important decrease in *γ^prfreq^* when excluded from the SFS are labeled. Estimates of *γ^prfreq^* in the control cohort is also indicated for comparison.](pgen.1001318.g002){#pgen-1001318-g002}

Discussion {#s3}
==========

Using approaches that specifically analyze both the function and accumulation of rare variants in disease cohorts, we have found a number of candidate genes associated with ASD and schizophrenia in two cohorts with sample sizes substantially smaller than those required for GWA studies. Population genetic approaches are designed to deal with data where sample sizes are limited compared to the sizes required in GWA studies. In both the ASD and schizophrenia cohorts, *GRIN2B* and *MAP1A* contain a statistically significant excess of rare missense variants, while the excess of rare missense variants in *CACNAF1* was restricted to the ASD cohort. The involvement of a particular gene (e.g. *GRIN2B* or *MAP1A*) in the etiology of both disorders may reflect a critical role for neurodevelopment processes and suggests a pleiotropic effect [@pgen.1001318-Carroll1]. Population genetic models incorporating demographic and selection processes, implemented in *prfreq*, corroborated this result for *MAP1A* and *CACNA1F*, and identified three new candidate genes: *GRIN3B*, *NOS1*, *RPGRIP1* ([Table 3](#pgen-1001318-t003){ref-type="table"}).

10.1371/journal.pgen.1001318.t003

###### Nominal *P* Values of Identified Candidate Genes Exhibiting Excesses of Rare Variants.

![](pgen.1001318.t003){#pgen-1001318-t003-3}

  ASD                                                                                                             
  ----------- ----------------------------------------- -------- ---------------------------------------- ------- --------------------------------------------------
  *GRIN2B*                      0.016                    0.047    0.001[\*](#nt107){ref-type="table-fn"}   0.75                     −7.311 (−5.9)
  *GRIN3B*                      0.01                      0.23                      NA                     0.015                          NA
  *CACNA1F*                     0.103                    0.028    0.001[\*](#nt107){ref-type="table-fn"}    NA     −0.691[\*\*](#nt112){ref-type="table-fn"} (1.94)
  *MAP1A*      0.0001[\*](#nt107){ref-type="table-fn"}   0.0004                     NA                     0.015                          NA
  *NOS1*                        0.429                    0.536                      NA                     0.75                      1.93 (5.68)
  *RPGRIP1*                     0.468                    0.162                      NA                     0.015                     2.02 (0.55)

  Schizophrenia                                                                                                       
  --------------- ----------------------------------------- -------- ---------------------------------------- ------- -------------------------------------------------
  *GRIN2B*                          0.057                    0.139    0.001[\*](#nt107){ref-type="table-fn"}   0.96                      −7.6 (−5.9)
  *GRIN3B*                         0.0029                    0.018                      NA                     0.005                         NA
  *CACNA1F*                         0.362                    0.304                     0.14                     NA                           NA
  *MAP1A*          0.0001[\*](#nt107){ref-type="table-fn"}   0.0008                     NA                     0.01                          NA
  *NOS1*                            0.221                    0.142                      NA                     0.96    −2.04[\*\*](#nt112){ref-type="table-fn"} (5.68)
  *RPGRIP1*                         0.088                    0.298                      NA                     0.091                    0.015 (0.55)

NA, not assessed.

\*Significant after Bonferoni Multiple testing.

**^a^**Significant excess of missense and rare missense variants versus silent variants, compared to the rest of genes pooled together in each cohort and separately for X chromosome and autosomes.

**^b^**Significant excess of individuals with rare missense variants in a given gene. QNTS controls used for the ASD cohort and schizophrenia negative controls used for the schizophrenia cohort.

**^c^**Significant impact on the overall (autosomes) site frequency spectrum within each disease cohort.

**^d^**Mean *γ^mkprf^* of disease cohort and control in parentheses.

\*\*denote mean γ significantly more negative in the disease cohort than among QNTS (ASD), SN (SCZ), or Western-European controls. NA are for genes with no available divergence data.

Most of our mapped genes ([Table 3](#pgen-1001318-t003){ref-type="table"}, [Table S5](#pgen.1001318.s009){ref-type="supplementary-material"}) have been previously implicated in neurological disorders or in neurodevelopment. *MAP1A*, a member of the microtubule-associated MAP1 proteins family, is predominantly expressed in adult neurons and is involved in axon and dendrite development. Among other interactions, *MAP1A* participates in the linking of DISC1 to microtubules [@pgen.1001318-Halpain1]. DISC1 is a protein that was described as related to the pathogenesis of schizophrenia by linkage analysis of a Scottish family [@pgen.1001318-Blackwood1], [@pgen.1001318-StClair1] and confirmed among Finnish cohorts [@pgen.1001318-Ekelund1], [@pgen.1001318-Ekelund2]. The association between schizophrenia and eleven genes interacting with DISC1 (including *MAP1A*) was explored in Finish families, with significant results in three of the candidates but not for *MAP1A* [@pgen.1001318-Tomppo1]. Among calcium channel classes of genes, such as *CACNA1F*, we found a significant excess of rare variants and two segregating inframe indels at CDS position 807 falling in a glutamic acid-rich coiled domain. *CACNA1F* has been previously associated to schizophrenia [@pgen.1001318-Wei1] and mutations have also been described for other neurological disorders [@pgen.1001318-Hope1]. Finally, two independent meta-analyses corroborate our findings for a role of *GRIN2B* in the etiology of schizophrenia [@pgen.1001318-Allen1], [@pgen.1001318-Li2]. *GRIN2B* codes a subunit of the glutamate and N-methyl-D-aspartate (NMDA) receptor. There exist several NMDA receptors that are constructed with one or more isoforms of the NR1 subunit (*GRIN1*) in different combinations with NR2 (*GRIN2A*, *GRIN2B*, *GRIN2C* and *GRIN2D* genes) and NR3 subunits (*GRIN3A* and *GRIN3B*) [@pgen.1001318-CullCandy1]. Some studies have suggested a relationship of decreased expression and abnormalities in NMDA receptors with schizophrenia [@pgen.1001318-Funk1], [@pgen.1001318-Kristiansen1]. Additionally, we observed key results for other NMDA related genes. *GRIN3B* had an excess of detrimental variants, two different analyses revealed significantly higher mapp scores in *GRIN3A* in the ASD cohort, while we observed a nonsense mutation in both *GRIN2C* and *GRIN3A* in our cohorts. In the case of *GRIN2B*, we also observed a coding indel which results in an amino acid insertion at cds position 1,353. This collection of rare and functional changes in the *GRIN* gene family points to an important role of NMDA receptors in these neurological disorders.

For some cases in our study, different methods identified different loci associated with ASD and Schizophrenia. Observing signficant disease associations for the same genes using all the methods employed would be ideal, however it is not expected as each statistical test evaluates a different component of variation within the data. Furthermore, the ability to use each test varies by chromosome (X vs. autosomal) and cohort. The Li and Leal collapsing method [@pgen.1001318-Li1] evaluates the accumulation of rare missense variants in genes in cases relative to controls, and is independent of silent variants. The ratio of missense to silent mutations is cohort specific and is used to identify genes that have an excess of missense mutations conditional on the number of silent mutations, relative to the cohort-wide average. As an example, a gene can have a minimum of two rare missense variants and generate a significant result with the collapsing method, but might not have sufficient power to test the ratio of rare missense to silent variants.

In contrast, we do expect genes with high missense to silent variant ratios, to have negative *γ^mkprf^* estimates, and to contribute to more negative *γ^prfreq^* estimates overall. We observed these patterns for the *GRIN2B* gene ([Table 3](#pgen-1001318-t003){ref-type="table"}) in both diseases which was supported by a significant collapsing method test result. Like *GRIN2B*, *CACNA1F* also shows concordance among methods within the ASD cohort; including a nominally significant missense to silent variant ratio, a significant collapsing method result, and a negative shift in the *γ^mkprf^* estimate relative to the control cohort. Finally, *MAP1A* has a significant ratio of missense to silent variants relative to the rest of the genes in both cohorts, and appears to have a signficant impact on the overall *γ^prfreq^* estimates for both the ASD and SCZ cohorts. Due to limited resequencing data in controls, we were unable to apply the collapsing method to *MAP1A*. In conclusion, for *GRIN2B*, *MAP1A*, and *CACNA1F*, we see concordant results among multiple methods when data availability allows testing by the different methods.

Previous studies demonstrate that genes associated with Mendelian disease or cancer have more negative population selection parameters compared to genes implicated in complex diseases [@pgen.1001318-Blekhman1]. This pattern may be explained by a late-onset effect, or by a potential enrichment of positively selected genes, among the loci involved in complex disease [@pgen.1001318-Blekhman1], [@pgen.1001318-Sabeti1]. Another explanation is that genes which accumulate either rare inherited or *de novo* mutations are also more likely to accumulate rare mutations which individually have either a high impact, as in the case of Mendelian disorders, or have an intermediate impact in aggregate.

In this paper we hypothesized that rare variants in neurologically expressed genes are enriched in ASD and schizophrenia cohorts. Our findings support a rare allele-major effect model as we have uncovered significant excess of rare variants in our disease cohorts. It remains an open question if ASD and schizophrenia are caused by variants found in a reduced set of genes such as *DISC1* or *NMDA* receptor related genes, or in a larger number of genes associated to the same functional class or pathway/network.

Materials and Methods {#s4}
=====================

Candidate Gene Selection {#s4a}
------------------------

In total, 408 genes were selected for sequencing: 122 in the X chromosome and 286 autosomal genes [@pgen.1001318-Awadalla1] ([Table S1](#pgen.1001318.s005){ref-type="supplementary-material"}) from a comprehensive list of potential synaptic genes (n = 5,000) based on published studies and databases [@pgen.1001318-Brachya1]--[@pgen.1001318-Zhang1]. X-chromosome synaptic genes were chosen due to the excess of affected males as compared to females in individuals affected with schizophrenia [@pgen.1001318-Lewis1] and ASD [@pgen.1001318-Skuse1], and since many genes affecting neurodevelopmental brain diseases happen to be on the X-chromosome [@pgen.1001318-Laumonnier1]. Autosomal genes implicated in synapse function, including those encoding glutamate receptors and their interactors were also chosen, because glutamate signalling is strongly implicated in synapse function [@pgen.1001318-Grant1]. A total of 38 genes (19 autosomal and 19 X-linked) with *de novo* mutations [@pgen.1001318-Awadalla1] or potentially disrupting protein mutations in the disease cohorts were chosen for sequencing in the controls.

Samples {#s4b}
-------

### Autism Spectrum Disorder (ASD) subjects {#s4b1}

Subjects diagnosed with autism spectrum disorders and both of their parents were recruited in clinics specializing in the diagnosis of Pervasive Developmental Disorders (PDD), rehabilitation centers, and specialized schools in the Montreal and Quebec regions, Canada [@pgen.1001318-Gauthier1]. Subjects with ASD were diagnosed by child psychiatrists and psychologists specialized in the evaluation of ASD. All subjects were diagnosed using the Diagnostic and Statistical Manual (DSM) of Mental Disorders criteria from patients in the Montreal and surrounding area, and depending on the recruitment site, either the Autism Diagnostic Interview-Revised or the Autism Diagnostic Observation Schedule was used. In addition, the Autism Screening Questionnaire (ASQ) was also completed for all of our subjects. All samples were French-Canadian. Furthermore, all proband medical charts were reviewed by a child psychiatrist expert in PDD to confirm diagnoses. Exclusion criteria were: (1) an estimated mental age \<18 months, (2) a diagnosis of Rett Syndrome or Childhood Disintegrative Disorder and (3) evidence of any other psychiatric and neurological conditions, specifically: birth anoxia, rubella during pregnancy, fragile-X disorder, encephalitis, phenylketonuria, tuberous sclerosis, Tourette and West syndromes. Subjects with these conditions were excluded based on parental interview and chart review. However, participants with a co-occurring diagnosis of semantic-pragmatic disorder (due to its large overlap with PDD), attention deficit hyperactivity disorder (seen in a large number of patients with AD during development) and idiopathic epilepsy (which is related to the core syndrome of AD) were eligible for the study.

### Schizophrenia subjects {#s4b2}

The schizophrenia subjects were selected from among several large schizophrenia clinical genetic research centers worldwide. These include: (A) The L.E. Delisi cohort collected in the USA and Europe [@pgen.1001318-DeLisi1]. Dr. DeLisi and her collaborators had identified and collected over 500 families with schizophrenia or schizoaffective disorder in at least two siblings over the last two decades. Diagnoses were done using the DSM-III-R criteria on the basis of structured interviews, review of medical records from all hospitalizations or other relevant treatments, and structured information obtained from at least one reliable family member about each individual. Two independent diagnoses (one made by Dr. DeLisi) were made for each individual in the study. In cases of disagreement between the diagnosing clinicians, a third diagnostician was consulted, and final diagnoses were made by consensus after discussion. In cases where there was a sibling diagnosed with schizophrenia, the case with earlier age of onset and more definite schizophrenia diagnosis was selected for the initial screening. (B) The R. Joober cohort: Dr. Joober has collected over 300 schizophrenia families in Montreal in the past 10 years [@pgen.1001318-Joober1]. The same clinical assessment procedures have been followed as in (A). In addition, extensive pharmacological data have been collected in this cohort. (C) The J. Rapoport cohort (USA): collection includes Childhood Onset Schizophrenia cases [@pgen.1001318-Gochman1]. Individuals in this cohort known to carry the VCFS deletion on chromosome 22q11 were excluded. All patients met DSM-IIIR/DSM-IV criteria for schizophrenia or psychosis not otherwise specified, had premorbid full-scale IQ scores of 70 or above and onset of psychotic symptoms by age 12 years. (D) Marie-Odile Krebs cohort (4 cases) was collected in France: All subjects were examined according to the standardized Diagnostic Interview for Genetic Studies (DIGS 3.0) [@pgen.1001318-Gourion1]. Family histories of psychiatric disorders were also collected using the Family Interview for Genetic Studies (FIGS). All DIGS and FIGS have been reviewed by two or more psychiatrists for a final consensus diagnosis based on DSM-IIIR or DSM-IV at each centre. Exclusion criteria for all subjects included neurologic hard signs (referring to any symptoms or neurological conditions that can come with psychosis (and not related to schizophrenia such as Parkinson, Alzheimers, etc.), a history of head trauma and substance abuse or dependence. Institutional ethical approval for the study and informed consent was obtained for all study participants.

From over 500 ASD and 1,000 schizophrenia families, 122 males and 20 females were selected for the ASD cohort, and 95 males and 48 females were selected for the schizophrenia cohort [@pgen.1001318-Awadalla1]. The random population cohort (150 males; 135 females) [@pgen.1001318-Awadalla1] consist of unrelated individuals collected for the Quebec Newborn Twin Study (QNTS) [@pgen.1001318-Lemelin1] where DNA samples were available for both parents and both twins (either monozygotic or dizygotic), however only one sibling was chosen randomly for sequencing.

DNA Preparation, Sequencing, and SNP Calling {#s4c}
--------------------------------------------

DNA samples were available for all affected and unaffected individuals and parents. For certain individuals where blood DNA was limited, we used DNA isolated from an Epstein-Barr Virus transformed lymphoblastoid cell line derived from the individual for the screen. The ASD cell lines samples have been frozen or regrown a maximum of two times. Genomic DNA was extracted from peripheral blood lymphocytes for each individual using Puregene extraction kits (Gentra System, USA). In all cases, rare variants were confirmed by sequencing both parents and using blood-derived DNA to rule out variations having arisen during production or growth of the lymphoblastoid cell line. Parentage was tested using 17 microsatellite markers. Primers were designed using the Exon Primer program from the UCSC genome browser. PCR products were sequenced at the Genome Quebec Innovation Centre in Montreal, Canada ([www.genomequebecplatforms.com/mcgill/](http://www.genomequebecplatforms.com/mcgill/)) on a 3730XL DNA Analyzer System. PolyPhred (v6.0) and Mutation Surveyor (v3.10, Soft Genetics Inc.) were used for mutation detection analysis. Initial screens were done on cell-line DNA from samples to conserve blood sample DNA. PolyPhred (v6.0) scores of 40 or higher were used as the threshold cut-off for all sequencing reads. When reads did not meet this criterion they were resequenced. Chromatograms for all rare variants (singletons or homozygous doubletons) were manually checked. The sensitivity of singleton detection was previously assessed by contrasting the heterozygote calls from the sequencing to heterozygote calls made from Affy SNPChip genotyping, obtaining an estimated false negative rate of heterozygote calls of ∼2% [@pgen.1001318-Awadalla1]. Variants passing all validation steps were retained for analysis, resulting in a high confidence dataset.

Population Structure {#s4d}
--------------------

*Structure* [@pgen.1001318-Pritchard3] was used to analyze the degree of population structure. Analysis of all samples showed no significant population structure as a large proportion of samples were of the same ethnicity. Principal Component Analysis (PCA) is more susceptible to samples with excess of private alleles and revealed genetic variability between individuals. We removed samples of non-European ancestry (self-reported ethnicity, ethnic outliers) and used *eigensoft* [@pgen.1001318-Price1] to identify and remove remaining genetic outliers (defined below). All autosomal variants excluding those with calls in less than 20 per cohort were used for PCA analysis (4,645 SNPs). We used the linkage disequilibrium correction and calculated the top 10 principal components (PCs) and removed individuals with PC projections greater than two standard deviations or more from the mean, for all significant principal components, using 10 iterations. Individuals exhibiting excess of rare variants genome-wide are likely to be genetic outliers and readily identifiable with PCA and removed, while individuals with an excess of rare variants in specific genes are retained. To ensure the PCA outliers were true outliers, we used a one-sided t-test to assess if the proportion of missense singletons in each PCA outlier was higher than in PCA retained samples across all autosomal genes (see [Text S1](#pgen.1001318.s010){ref-type="supplementary-material"}). *Structure* (admixture model) was used to reassess levels of population structure within the final sample set ([Figure S1C](#pgen.1001318.s001){ref-type="supplementary-material"}).

Computational Inferences of Mutation Severity {#s4e}
---------------------------------------------

Mapp was used to predict severity and assign scores to each missense variant. Orthologous protein sequences were obtained using the Galaxy Browser (<http://main.g2.bx.psu.edu/>) and the UCSC Human Genome Browser (hg18, <http://genome.ucsc.edu/cgi-bin/hgGateway>) to generate columns of aligned orthologous amino acids. Mapp scores and *P* values were calculated as shown in Stone and Sidow [@pgen.1001318-Stone1]. Mapp assesses variation observed at each amino acid position with respect to six physicochemical properties (hydropathy, polarity, charge, side-chain volume, free energy in alpha-helical conformation, and free energy in beta-sheet conformation) after weighting each protein sequence to mitigate the influence of phylogeny.

Statistical Analysis {#s4f}
--------------------

### Estimating population mutation rates and selection coefficients {#s4f1}

*Hclust* [@pgen.1001318-Luca1] was used to calculate *θ~W~*, and *π* for each gene in each cohort. Demographic parameters were inferred from the folded site frequency spectrum (SFS) of silent and intronic variants using *prfreq* [@pgen.1001318-Boyko1]. Conditioning on the demographic parameters from the silent and intronic SFS, the likelihood of the missense SFS was estimated for three models: a Wright-Fisher neutral population, the demographic model inferred form the silent and intronic variants, and a demographic with a selection parameter (*γ^prfreq^*) model. *P* values of model improvement were estimated by comparing the likelihoods, assuming a χ^2^ distribution of two times the differences in the likelihoods between the models. To compare the *γ^prfreq^* values estimated in the ASD and schizophrenia cohort to the *γ^prfreq^* values estimated in the control cohort, we computed the likelihood of the control parameters estimates in the schizophrenia and ASD cohorts, and compared these likelihoods to the likelihoods of the ASD and schizophrenia parameters estimates. We analyzed the effect of each gene with at least one missense variant (*n* = 198 autosomal genes) on the SFS by estimating *γ* in all the SFSs resulting from excluding the missense variants of each individual gene, in each cohort.

### Estimating individual gene selection coefficients {#s4f2}

The gene specific selection coefficient, *γ^mkprf^*, was calculated with the *mkprf* program [@pgen.1001318-Bustamante1] for each cohort (ASD, Schizophrenia, QNTS Controls). The number of synonymous and nonsynonymous changes between humans and chimpanzees was obtained from Bustamante, *et al.* [@pgen.1001318-Bustamante2] for 244 genes. Additionally, the European ancestry samples also reported in Bustamante, *et al.* [@pgen.1001318-Bustamante2] were used as a secondary control data set for this analysis.

Within-Gene Excess of (Rare) Missense Variants {#s4g}
----------------------------------------------

Fisher\'s exact test was used to detect deviations in the missense to silent variant ratio within genes. For each gene, the ratio of missense (or rare missense) to silent variants was contrasted to the same ratio in all remaining genes. This analysis was conducted in the ASD and schizophrenia cohorts testing autosomal and X-linked genes separately. We used the Bonferroni correction for multiple tests (n = 277). Excess of predicted deleterious load within genes was evaluated by summing the mapp scores for all missense variants within a gene and testing the ratio of summed mapp scores to silent variants within the gene relative to all other genes. This was done separately for autosomes and X-linked genes, and separately for each disease cohort.

Genes with Excess of Individuals Harboring Rare Missense Variants {#s4h}
-----------------------------------------------------------------

To identify genes with an excess of individuals bearing rare missense variants, we used Li and Leal\'s collapsing method [@pgen.1001318-Li1]. For ASD vs schizophrenia, ASD vs QNTS, and schizophrenia vs QNTS controls, the number of individuals with at least one rare missense mutation and the number of individuals with no rare missense variants was determined for each cohort, and these counts made up the cells of the two by two table. We assessed statistical significance using Fisher\'s Exact test and used Bonferroni\'s correction for multiple tests (number of genes *n*~ASD-SCZ~ = 277, *n*~ASD\ --\ QNTS\ Controls~ = 26, *n*~SCZ-\ QNTS\ Controls~ = 26). This analysis was repeated, considering only missense variants with a mapp score \>10.

Supporting Information {#s5}
======================
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Population Structure of the Disease Cohorts. Principal component analysis (A, B) and *structure* analysis of the disease cohorts (C). In S1A and S1B, each dot denotes a sample\'s position in the top 2 principal components for A) all samples sequenced and B) samples after excluding ethnic and PCA outlier filters. Figure C show the structure results for the model of K = 2 populations. Each column corresponds to a sample, red represents ancestral population 1, and blue represents ancestral population 2. *q* is the proportion of the genome from each ancestral population.
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Mapp values in common versus rare variants. Rare is defined as minor allele frequency \<0.03.
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Excess of Missense Variants by Gene. Fisher Exact Test *P* of the proportion of A) missense to silent variants and B) rare missense to all silent variants, at each individual locus compared to those proportions in the rest of the genes in the ASD and SCZ cohorts.
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Observed and Expected Site Frequency Spectrum. Observed and expected site frequency distributions for the SNPs the ASD (A), SCZ (B), and controls (C) cohorts. Expected distributions have been obtained under a neutral model not including demography, a model with demography, and a model with demography and selection.

(0.28 MB EPS)

###### 

Click here for additional data file.

###### 

Genes Resequenced.
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Counts for Silent to Missense Variant Ratios in MAP1A.
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Counts for Collapsing Method for Significant Results.
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Prfeq Maximum Likelihood Estimates of Demographic and Selective Models. aAutosomal mutations only. b χ2 (P value) with degrees of freedom being the difference of the number of estimated parameters. TAU is the time in generations since the non-stationary dynamics, sclaed by 2\*Ncurr. TAU B is the scaled time of the bottleneck. OMEGA is the ratio of ancestral to current Ne.
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Variants found in MAP1A, CACNA1F, and GRIN2B.
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Population Structure.
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